Why Phage Therapy May Fail
From Editors in Conversation · · 37 min
This plays from the publisher's own server. We do not host a copy.
Description
Phage therapy has gained a lot of traction but the challenges created by this approach have not been properly assessed at a big scale. We often read about therapy successes on isolated cases but, rarely, we read or hear about failures. AAC recently published a case series of patients who failed phage therapy. Today, we will discuss this topic with the principal investigator on the research.
Topics discussed: - Phage therapy as an approach for MDR bacteria.
- The challenges of phage therapies.
- Issues that can influence the success of phage therapy
Guest: - Saima Aslam, MBBS. Director, Solid Organ Transplant Infectious Diseases Service, Professor of Medicine, University of California, San Diego.
Article: Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases https://journals.asm.org/doi/10.1128/aac.01728-23
Questions Answered: - How are we doing with phage therapy at this point?
- What are the challenges to deploy phage therapy in clinical settings?
- The 5 cases of failure of phage therapy in patients with LVADs summarized
- What factors did Dr. Aslam identify that were related with the failure?
- How do you develop neutralization against phages and how can you prevent it?
- Bacterial isolates with varying phage susceptibility, how can this be detected?
- What did Dr. Aslam learn?
- Future research
This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org (https://aac.asm.org). If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership (https://asm.org/membership) to sign up.
Visit journals.asm.org/journal/aac (https://journals.asm.org/journal/aac) to browse issues and/or submit a manuscript.